Against the background of private medical care , many investment institutions have focused their attention on high-end areas.
On January 9, the reporter learned from Shenzhen Gaotejia Investment Group that it has reached a strategic cooperation with Meihua Medical Group and will invest 200 million yuan in Meihua Medical in 2017. However, the details of the cooperation and the shareholding of the shares did not disclose details. In an interview with reporters, Gao Tejia pointed out that the company will also increase capital according to specific conditions.
Wang Wenhua, executive director of CIC Knowledge Consulting, pointed out that in the development of high-end medical services, the market and capital have become the most primitive driving force. However, Shi Lichen, the founder of the third-party medical service platform, said that at present, the problems of taxation, doctor resources and brand awareness of private hospitals are still challenges.
Time to go to Hong Kong for listing is already under planning
Meihua Medical Group focuses on the field of women's services and positions high-end.
Huang Qing, executive vice president of Gao Tejia Investment Group, said that China's women's and children's medical service industry maintains double-digit growth every year, and high-end service demand is constantly being released, hoping to have a layout in this market.
It is worth mentioning that there are not many cases of listing high-end women and children hospitals in China. Not long ago, New Century Medical, a private women's and children's medical service provider whose main business is located in Beijing, has been heard through the Hong Kong Stock Exchange and is about to land on the Hong Kong stock market. Does Meihua have a similar plan?
“As long as it is connected with capital, listing is definitely an inevitable way. From the capital entry period, we must prepare them for exit. But listing is definitely not a goal, and capital docking is to add leverage to what we do. Our principle To do a good job of their own affairs, moderately add leverage. In this regard, Guo Yuqiao, chairman of Meihua Medical Group, said that the specific time to market is also under planning.
“Gao Tejia’s investment is mainly for pre-IPO investment. Meihua wants to optimize its shareholding structure and introduce strategic investors. This is a process of strengthening management.†Shi Lichen told reporters that enterprises should improve their management level and optimize before listing. The shareholding structure can make the market value easy to upgrade. In addition, the entry of certain strategic investors is easier to gain outside recognition.
Nucleic acid extractor is an instrument that uses matching nucleic acid extraction reagents to automatically complete specimen nucleic acid extraction. It is widely used in various fields such as the Center for Disease Control, clinical disease diagnosis, blood transfusion safety, forensic identification, environmental microbiological testing, food safety testing, animal husbandry and molecular biology research.
automatic nucleic acid extractor,DNA extractor,RNA extracting machine,dna extraction equipment,rna extraction equipment
Shenzhen Uni-medica Technology Co.,Ltd , https://www.unimedicadevice.com